Background: Equitable access to health care is a goal subscribed to in many European economies. But while a growing body of literature studies socioeconomic inequalities in health service use, relatively little is still known about inequalities in medicine consumption. Against this background, this study investigates the (socioeconomic) determinants of medicine use in the Austrian context. Methods: Multivariate logistic regressions were estimated based on the European Health Interview Survey, including representative information of the Austrian population above age 25 (n = 13 291) for 2006/2007. As dependent variables, we used prescribed and non-prescribed medicine consumption as well as prescribed polypharmacy. Socioeconomic status was operationalized by employment status, education and net equivalent income. Health indicators (self-assessed health, chronic conditions), demographic characteristics (age, sex) and outpatient visits were included as control variables. Results: Socioeconomic status revealed opposing utilization patterns: while individuals with higher education and income were more likely to consume nonprescribed medicines, the less educated were more likely to take prescribed medicines. Lower socioeconomic groups also showed a higher likelihood for prescribed polypharmacy. For the consumption of both medicine types, the main socioeconomic determinant was high income. In an additional analysis, lower socioeconomic groups were found to more likely report prescription purposes as the main reason for consulting a practitioner. Conclusion: These results point to different behavioural responses to ill health, not least determined by institutional incentives in the Austrian health care system. 
Introduction
E quitable access to health care is a goal subscribed to across Europe. 1 In the past decade, a great deal of research has been devoted to socioeconomic inequalities in health service utilization. [2] [3] [4] Surprisingly little, despite its importance for individual health, however, is still known about socioeconomic differences in medicine consumption, which may stem from various sources:
inequalities in access to pharmacies/physicians, physicians' treatment strategies, communication barriers, differences in self-treatment strategies or compliance to medical advice, be it based on individual preferences or financial barriers. 5 Existing research mainly concentrated on the socioeconomic determinants of prescribed medicine use for specific symptoms [6] [7] [8] and/ or was restricted to certain age groups. [9] [10] [11] Only a handful of studies focused on prescribed pharmaceutical use by socioeconomic position in general, [12] [13] [14] and also only limited evidence is available on non-prescribed medicine consumption. 15 Even fewer publications have yet explored the association between socioeconomic position and prescribed vs. non-prescribed pharmaceutical use. 16, 17 From a policy point of view, however, such an analysis may provide valuable insights. In the case of Austria, as addressed in this article, it may not only allow for conclusions on which socioeconomic groups more likely use mostly publicly funded (prescribed medicines) or privately funded (non-prescribed medicines) health care services, but also on socioeconomically influenced behavioural responses to ill health. Furthermore, such analysis may help explore the congruence of utilization patterns with the health system's implicit incentive structure.
The Austrian health care system is based on a social insurance model. It covers 98% of the population and guarantees almost free access to most forms of medical care: for instance, no gatekeeping is in place and for the vast majority of the insured and their dependants (80%), outpatient consultations do not incur co-payments. Its main sources of funding are income-based social insurance contributions, followed by taxes and private payments. 18 Around 13% of the total health care expenditure, in 2007, was spent on pharmaceuticals. About 65% of pharmaceutical spending is publicly funded. 19 About 80% of authorized pharmaceuticals are prescription medicines. Over-the-counter (OTC) medicines account for around 20% of the average pharmacy turnover. 20 Regarding pharmaceutical supply, the insured population is granted access to all medicines specified on a positive list. Prescribed medicines (which may also include OTC medicines when prescribed by a doctor) can be obtained at any pharmacy with a valid prescription. Per prescribed item, patients pay a flat fee (2006: E4.60; 2007: E4.70), except for medicines costing less than this fee, for which only their (lower) price is to be paid. The remaining costs are fully covered by the social insurance agencies. Individuals (and their co-insured dependants) in particular need of financial protection, including asylum seekers, people with certain communicable diseases and recipients of specific social benefits, are a priori exempt from paying prescription fees. People below certain net income thresholds can likewise apply for such exemption. Non-prescribed medicines are (only) available at pharmacies for the (self-) treatment of less severe illnesses and have to be fully paid out of pocket. In rural regions, for easier access, practitioners can also dispense prescribed and nonprescribed medicines to their patients. In exceptional circumstances, pharmaceuticals not included in the positive list may also be prescribed and then reimbursed. [19] [20] [21] Against this background, the objective of this article is to investigate the socioeconomic determinants (approximated by employment status, education, income) of prescribed and non-prescribed medicine use in the Austrian outpatient sector. For prescribed pharmaceuticals, we additionally look at polypharmacy to determine socioeconomic differences in the intensity of medicine use. Given the institutional context, in particular private funding requirements, equitable access for equal need is expected for prescribed medicine consumption, while for non-prescribed medicines, people with higher socioeconomic position are hypothesized to more likely report such use. The results are discussed not only in light of institutional incentives but also regarding socioeconomic differences in behavioural responses to ill health based on reasons for general practitioner (GP) consultations, thus adding new insights to the literature.
Methods

Data collection and sample
The study draws on cross-sectional data from the European Health Interview Survey (EHIS), collected in Austria between March 2006 and February 2007 (response rate: 63.1%), 22 with sample stratification by geographic region and weighting by geographic region, age and sex. 23 Trained interviewers conducted home-based, computerassisted personal interviews on health-related topics and sociodemographic characteristics, resulting in data on 15 474 individuals above age 15. However, as socioeconomic status is not fully established at this young age, 14 we restrict our analysis to those aged 25 and over (n = 13 291).
Variables
The dependent variables are based on the following questions: 'During the past 2 weeks, have you used any medicines that were prescribed for you by a doctor?' and 'During the past 2 weeks, have you used any medicines not prescribed for you by a doctor?' Prior to asking these questions, medicines were verbally defined as including homeopathic products, vitamins and minerals, sleeping and anodyne pills, unguents or injections. If a positive answer was given, the respondents were presented a list with specific groups of medicines (prescribed medicines: medicines for asthma; chronic bronchitis, chronic obstructive pulmonary disease, emphysema; high blood pressure; lowering the blood cholesterol level; other cardiovascular disease; joint pain; headache or migraine; other pain; diabetes; allergic symptoms; stomach trouble; depression; tension or anxiety; sleeping tablets; antibiotics; contraceptive pills; menopausal hormones, andropause or osteoporosis; other medicine; non-prescribed medicines: medicines for joint pain; headache or migraine; other pain; cold, flu or sore throat; allergic symptoms; stomach trouble; vitamins, minerals or tonics; other type of medicine or supplement). In this context, it seems noteworthy that prescribed and non-prescribed medicines may not be considered as perfect substitutes for each other: whereas prescribed (reimbursable) alternatives may be available for non-prescribed medicines, non-prescribed medicines are typically used in case of malaise and thus less severe health problems. 24 For each individual group of medicines listed, respondents were asked to declare their use by stating yes or no. For our analysis, this information was summarized into non-prescribed medicine use (only), prescribed medicine use (only) and use of both types of medicines. To allow for unbiased gender comparisons, use of contraceptives and medication for menopause, andropause or osteoporosis (n = 155) were treated as 'no medicine consumption'.
Regarding polypharmacy, that is, the use of multiple prescribed medicine 'groups' in the last 14 days, we distinguished between minor polypharmacy (prescribed medicine use of two or three groups) and major polypharmacy (four groups or more). 12 As independent variables of interest, we opted for three commonly used 25 proxies for socioeconomic status. First, employment status was categorized into employed (reference group), unemployed, homemaker/other (e.g., in parental leave) and retired, and may thus be considered as a proxy for individual time constraints, which supposedly also affect individual health behaviour. Second, education potentially relates to health literacy (despite not being a perfect measure), as they are commonly found to be correlated. 26 Education was measured by the highest level completed: basic education (reference group), apprenticeship/ vocational school, secondary education without diploma, secondary education with diploma or post-secondary education, and tertiary education. Third, as a link to financial barriers, we included income, approximated by the monthly net equivalent income in Euro based on the Organisation for Economic Co-operation and Development (OECD)-modified scale 27 and summarized into 700 (reference group), 701-1050, 1051-1400, and !1401.
Physician contacts were included as a control variable, as they are expected to be a strong predictor especially for prescribed medicine consumption. They were measured by the number of outpatient physician (GP, specialist, or in hospital outpatient ward) consultations in the last 4 weeks, 28 categorized into no such visit (reference group), one visit and two or more visits. To control for demographic factors, we included age (in six categories) and sex, with the youngest and men being the respective reference groups.
Finally, since a socioeconomic gradient in health disadvantaging the poor is well-established, 29, 30 we took account of the number of chronic diseases (none as reference group vs. one, two and three or more chronic conditions) prevalent in the last 12 months and also introduced self-perceived health status. The latter variable is based on the following question: 'How is your health in general? Is it very good, good, fair, bad or very bad?' Answers were summarized into three dimensions: poor (including bad and very bad), mediocre (fair) and good (very good, good) as reference group.
In an additional analysis, the reported main reason for the last GP consultation was included as dependent variable. Responses were categorized into preventive motives (preventive check-up or administrative causes; reference group), acute treatment (treatment of an accident, disease, check-up or others) and prescription of pharmaceuticals. As differences in demographic and health characteristics may partly explain differences in respective responses, we controlled for these variables.
Statistical analysis
To determine the association between socioeconomic status and pharmaceutical consumption, multinomial multivariate logistic regressions were carried out (using Stata 13.1). In these models, the probability was estimated of falling into certain categories compared with the reference category. To check the statistical significance of the calculated relative-risk ratios, z-statistics were used. Only results with P < 0.05 were considered statistically significant and thus discussed further. As a measure of model fit, McFadden's R 2 is reported.
Results
Descriptive analysis
In terms of general medicine use (table 1) , during the 2 weeks before the interview, 64% reported taking some medicine; while 1 in 10 Austrians of the sample (10%) consumed non-prescribed medicines, 4 in 10 (41%) consumed prescribed pharmaceuticals. The remaining 13% used both types. As for prescribed medicines, taking two or three groups was most common (43%). Both women (43%) and men (39%) took more prescribed medicines than non-prescribed medicines (11% and 9%, respectively), and women showed a higher share of pharmaceutical use in general. This holds especially true for the consumption of both types of medicines (women: 16%; men: 8%).
Overall, except for non-prescribed pharmaceuticals, medicine use increases with age.
Logistic regressions
Differentiating between prescribed and non-prescribed medicines (table 2) , an opposing socioeconomic gradient emerges: while lower education increases the probability for prescribed medicine use, non-prescribed medicine use increases with higher levels of education and for the highest income group. Regarding other influencing factors, the general patterns are similar for both types of medicines, albeit with differences in magnitude. Health-related factors exert a much higher impact on the relative risk of prescribed medicine use than on non-prescribed medicine consumption. Furthermore, outpatient visits are a strong predictor for prescribed medicine use.
For prescribed polypharmacy (table 3) , the impact of socioeconomic characteristics only becomes apparent at the point at which four or more groups of medicines are being consumed.
Finally, regarding the main reason for the last doctor consultation (table 4), lower socioeconomic status increases the chance of primarily seeing a GP for prescription purposes only. Also, lower socioeconomic groups more likely consult a GP because of acute treatment in contrast to prevention.
Discussion
In terms of key findings, the logistic regression analyses on the influence of socioeconomic position (controlling for health, physician consultations and demographic characteristics) may be summarized as follows. Opposing utilization patterns are identified: for non-prescribed medicines, both high income and even more so high education increased the likelihood of taking these medicines. For prescribed medicine use, in contrast, we found an education gradient suggesting that the less educated have a higher chance of such medicine consumption. Also, individuals outside the employment market, presumably owing to fewer time constraints, are more likely to take prescribed medicines. Regarding prescribed and non-prescribed pharmaceuticals combined, the wealthy are attributed to a higher consumption likelihood. In these contexts, higher use is generally considered as proxy for access to pharmaceuticals. However, an opposing interpretation is typically associated with polypharmacy due to potential health risks. According to our analysis, the use of four or more groups of prescribed pharmaceuticals was related to both lower education and income.
As for age and gender, our results are in line with previous studies, [31] [32] [33] whereas international evidence is mixed on the socioeconomic gradient. While a Danish study 16 likewise found an increase in prescription medicine use among lower socioeconomic groups, no such correlation existed for OTC medicines. In Barcelona, another study 17 concluded that among those with poor health, social class is positively associated with prescribed medicine use. Also, among men with good health, the more advantaged classes more likely took non-prescribed medicines. In a similar analysis of Austrians in poor health (data and results not shown), non- prescribed medicine use was also more likely among the highly educated population, whereas there was no association for prescribed medicine consumption. In a Greek study, 12 university education increased the likelihood of prescribed medicine consumption; for prescribed polypharmacy, though, no social gradient was found. The same applies to a Swedish study 11 on polypharmacy among elderly people, whereas for elderly men in South Wales, polypharmacy was related to a lower socioeconomic position. 34 This study sheds light on a variety of previously rather uncharted aspects of equity in health care utilization. Nevertheless, several limitations apply. First, since the data used are based on self-reported information from EHIS, measurement errors may be an issue, especially for medicine consumption. To minimize these risks, interviewers were instructed to define medicines broadly and present a list with specific groups of medicines. Together with a recall period of 2 weeks, this likely increases the reliability of the information given. Generally, interviewer trainings, the use of a handbook including extensive explanations and the use of computer-assisted personal interviewing software enhance the data quality. Regarding selfreported health, this does not perfectly control for socioeconomic variations in health. However, including chronic conditions in our analysis will partly capture respective differences. As for the income variable, suffering from item non-response in 25% of cases, imputation was based on the estimated income distribution derived from the European Union Statistics on Income and Living Conditions (EU-SILC) survey. 23 Finally, in the context of medicine use, household surveys are an acknowledged standard tool in health policy research. 35 Second, polypharmacy as used in this study is based on the number of medicine groups consumed. It is thus to be seen as a (conservative) indication for the 'number' of medicines, which is the commonly applied definition of polypharmacy.
Third, our findings do not allow for final inferences on whether the socioeconomic inequalities in prescribed medicine use are physician mediated or patient mediated: in the case of no medicine use, we cannot differentiate among an individual's lacking receipt of Notes: Multinomial logistic regression with no medicine use as reference group (n = 4812). Likelihood-ratio chi-square = 7770.99 (df = 69, P < 0.0001) and McFadden's R 2 = 0.24, n = 13 291. CI = confidence interval; df = degrees of freedom; n = number of cases; RRR = relative-risk ratios. **Significant at 5%; ***significant at 1%. a prescription, an individual's lacking need for medicines or an individual's choice not to fill a prescription. For instance, only about 70% of Austrians fully comply with pharmaceutical advice. 36 Fourth, cross-sectional data as well as the statistical approach chosen may evoke problems with endogeneity. On the one hand, since we assumed health conditions to be explanatory variables for medicine consumption, one might argue that causality also runs in the opposite direction. In our data, however, the question on medicine use covers the last 14 days, whereas self-perceived health relates to an individuals' general assessment (rather than the present state) and chronic conditions are long lasting by definition. For the time frames given, it thus seems unlikely that the health indicators used are highly affected by (recent) medicine use. On the other hand, using both socioeconomic characteristics and health conditions as explanatory variables does not account for their potential interrelation. Given the aim of our analysis, however, and in line with the literature, 6 we consider this to be outweighed by the importance of including health indicators so as not to overestimate any potential inequities in medical use.
This study indicates a socioeconomic gradient in the reliance on different pillars of the Austrian health care system. For instance, lower socioeconomic groups by using prescribed medicines are more likely to rely on publicly subsidized resources. This can be partially explained by differences in the financial ability, an unequal distribution of health literacy across socioeconomic groups 26 and related differences in health-seeking behaviour. 28 Our analysis of the main reason for the last doctor consultation attributes lower socioeconomic groups a higher chance for seeing a GP for prescription purposes or acute treatments. These findings thus add evidence to earlier interpretations on medicine use as to a socioeconomic gradient in responses to ill health. 10 Given that prescribed and non-prescribed medicines are not perfect substitutes, but serve as treatment for medical conditions of varying severity, our findings also hint at an inherent time dimension driving individual behaviour: higher socioeconomic groups, due to their increased financial means and health literacy, seem to be more likely to opt for timely, selfinitiated treatment strategies (including the use of non-prescribed medicines) instead of having to wait for a doctor's appointment. Notes: Multinomial logistic regression with use of 1 group as reference group (n = 2022). Likelihood-ratio chi-square = 2375.86 (df = 46, P < 0.0001) and McFadden's R 2 = 0.21, n = 5457. CI = confidence interval; df = degrees of freedom; n = number of cases; RRR = relative-risk ratios. **Significant at 5%; ***significant at 1%.
In theory, the accruing out-of-pocket pharmaceutical copayments (2007: E4.70) may seem a tax on the financially disadvantaged ill. 37 In practice, however, around one out of four insured Austrians are exempt from prescription fees. 38 In addition, in 2008, a regulation mandated an out-of-pocket cap at 2% of the preceding year's total annual net income to further disburden those with high medication needs. Once exceeded, patients are then charged no prescription fees until the end of that calendar year. In 2008, this regulation benefitted 273 000 Austrians. 39 Consequently, and as confirmed by our analysis even for the year prior to introduction, prescribed medicine use seems no matter of income. On the other hand, due to lacking incentives in the pharmaceutical reimbursement system, Austrians are rather price insensitive and typically not aware of actual pharmaceutical costs. 24 Indeed, increasing medicine consumption and thus rising costs have, in the last decade, also caused political concern. 39 
Conclusion
Public health policy in Austria seems successful in guaranteeing lower socioeconomic groups equitable access to prescribed pharmaceuticals, which account for 80% of authorized pharmaceuticals in this country. A pro-rich gradient, however, is observed for nonprescribed medicine use which may indicate a worse treatment of minor health problems or delayed treatment among the worse off. These results together with the analysis of the main reasons for consulting a GP point to different behavioural responses to ill health that are not least determined by institutional incentives in the Austrian health care system. For future research, both results and limitations of this study indicate a need to also use claims data to overcome the shortcomings of self-reported data and point at the importance of disentangling responses to ill health and the impact of the institutional context when investigating the determinants of inequalities observed. Notes: Multinomial logistic regression with preventive motives as reference group (n = 1300). Likelihood-ratio chisquare = 950.66 (df = 42, P < 0.0001) and McFadden's R 2 = 0.05, n = 10 862. CI = confidence interval; df = degrees of freedom; n = number of cases; RRR = relative-risk ratios. **Significant at 5%; ***Significant at 1%.
